SUMMARY Synthesis of prostanoids in Crohn's disease was investigated using rectal biopsy specimens maintained in organ culture. As with ulcerative colitis increased synthesis of prostaglandin (PG)E2 was observed when the mucosa was inflamed, compared with uninflamed mucosa in Crohn's disease, and with control biopsy specimens. In contrast with ulcerative colitis differences from control specimens were observed even in the absence of inflammation. There was a raised synthesis of thromboxane (Tx)B2 (stable breakdown product of TxA2); concentrations of 6-keto PGFl, (stable breakdown product of prostacyclin) were unchanged and* hence the ratio of 6-keto PGF1jTxB2 was reduced. These changes might lead to an. altered cytoprotective capacity or reduced suppressor cell activity, such as has previously been reported in intestinal lymphocytes in Crohn's disease.
In ulcerative colitis several studies have shown that increased synthesis of prostanoids such as PGE2, PGF2a, TxB2, and 6-keto PGF1a: occurs during relapse.1'4 Fundamental differences from normal have not been shown in remission. The significance of these findings is unclear as thromboxane A2 and prostacyclin have powerful opposing actions and it has been suggested that an imbalance in the synthesis of these two prostanoids may be of pathological significance in several disease states.5
Data on mucosal prostaglandin synthesis in Crohn's disease are lacking although peripheral blood mononuclear cells have been shown to synthesise increased amounts of PGE2 and TxB2 during relapse.6 In the present study we have investigated basal synthesis of PGE2, TxB2, and 6-keto PGF1, by rectal mucosa from patients with Crohn's disease maintained in organ culture. The study shows a deviation from normal in the synthesis of TxB2 and its relationship to 6-keto PGFIa: even in the absence of inflammation.
with seven control patients (mean age 531 ±9.3 years). All the patients studied were British. The diagnosis of Crohn's disease was established on the basis of histology of biopsy or resected specimens and on radiological appearances. Details of the distribution of the Crohn's disease based upon evidence available at the time of biopsy are shown in the Table. Inflammation was judged on sigmoidoscopic appearances supported by a routine histological examination. All biopsies that were considered inflamed came from reddened areas with loss of vascular pattern, granularity, and either spontaneous haemorrhage or haemorrhagic friability. The mucosa was considered uninflamed if it was pearly with a clearly visible vascular pattem and no sign of haemorrhage. Biopsies from equivocal mucosa were not used. At the time of study the rectal mucosa was diffusely inflamed in seven cases; five patients had rectal disease sufficiently localised for biopsy specimens from both sigmoidoscopically inflamed and uninflamed mucosa to be taken. In six cases the rectal mucosa was uninflamed and in four of these the disease was apparently confined to the small bowel or ileocaecal region and there had never been evidence of rectal involvement. The drugs used in the treatment of Crohn's disease at the time of biopsy were sulphasalazine (n=4), prednisolone (n= 1), sulphasalazine and prednisolone (n=3), or sulphasalazine and azathioprine (n=2); seven patients were untreated at the time of biopsy. The control biopsy specimens were taken during the investigation of untreated patients with irritable colon syndrome (n=2), gastrointestinal blood loss (n=2), transient diarrhoea (n=l), small bowel lymphoma (n=1), and for the exclusion of amyloid (n=1). The specimens were histologically normal and in none was any organic 0 Rectum uninvolved disease involving the rectum shown. Rectal biopsy specimens were excised 6 to 10 cm from the anus by forceps biopsy. The median biopsy weights were 8 mg (range 5-18 mg) for the patients with Crohn's disease and 13 mg (3-16 mg) for the control patients. After excision the biopsy specimens were washed in RPMI 1640 culture medium and cleaned of blood. They were placed in organ culture2 3 using RPMI 1640 containing penicillin (100 U/ml) and streptomycin (100 ug/ml) and cultured at 37°C in a vacuum jar containing 95% oxygen/5% CO2. No fetal calf serum was added to the medium as albumin interferes with the assay of TxB2. 4 The culture medium was changed after one hour and the culture continued for a further 23 hours. The synthesis of PGE2, TxB2, and 6-keto PGFW1, judged by their accumulation in the medium at the end of culture, was measured, as previously described,4 by specific radioimmunoassays, performed without knowledge of the source of the samples. Fig. 1 .
Where paired comparisons were made in patients with patchy involvement of the rectum all five showed greater synthesis of PGE2 by sigmoidoscopically inflamed than by uninflamed mucosa.
(ii) TxB2: The median amounts of TxB2 synthesised in Crohn's disease were 0.70 ng/mg, 1.89 pmol/mg (inflamed mucosa n=11) and 0-90 ng/mg, 2.43 pmol/mg (uninflamed mucosa n=11). These values did not differ significantly from each other but with both inflamed and uninflamed mucosa the synthesis of TxB2 was significantly higher than was observed in the control patients (median synthesis 0 18 ng/mg, 049 pmol/mg, n=7, p<005 compared with uninflamed, p<002 compared with inflamed mucosa from patients with Crohn's disease). High rates of TxB2 synthesis were seen in two of the patients with Crohn's disease where the rectum was apparently uninvolved.
(iii) 6-Keto PGFIf: No significant differences could be shown for the synthesis of 6-keto PGF1<, between inflamed (median 0.63 ng/mg, 1*70 pmol/mg) or uninflamed mucosa (median 0.33 ng/mg, 0-89 pmol/ mg) from patients with Crohn's disease or uninflamed mucosa from the control patients (median 041 nglmg, 1.11 pmol/mg). The ratio of 6-keto PGF1<X to TxB2 synthesis, however, was significantly higher in the control biopsy specimens (median ratio 1.47) compared with both inflamed (median ratio 052; p<0.05) and uninflamed mucosa (median ratio 0*62, p<0.02) from patients with Crohn's disease. The difference between the control biopsy specimens and those with uninflamed mucosa with Crohn's disease remains significant (p=005) if the uninflamed biopsy specimens from patients with localised inflammation are excluded.
Six of the seven control patients showed a ratio greater than 1-0 whereas in only six out of 22 of the specimens from patients with Crohn's disease was it greater than 1.0. These results are shown in full in Crohn's disease, even in the absence of inflammation, was unexpected but might be of pathogenic significance. It could have arisen artefactually as a result of occult inflammation in apparently normal mucosa but against this proposition is the fact that an analogous effect was not shown for PGE2. Furthermore, the raised synthesis of TxB2 in two patients who had never had apparent rectal involvement raises the possibility -which requires confirmation -that this change may occur in the absence of clinically evident disease. As the possibility of analogous consequences in the colon. Such a conclusion, however, must remain speculative as substantial doubt exists whether prostacyclin has any action affecting the colon which can reasonably be described as cytoprotection. Prostaglandin synthesis in inflammatory bowel disease has previously been seen in terms of the genesis of the mucosal inflammation and a global increase in the synthesis of prostanoids. We have used the ratio of prostacyclin to thromboxane synthesis to draw attention to the importance of the balance between synthesis of prostanoids with differing inflammatory, immunological, or perhaps 'cytoprotective' properties. The effect of treatment on this balance requires further clarification. Other imbalances might have been apparent if lipoxygenase products had been measured and the results emphasise the need to define further the spectrum of potential inflammatory mediators synthesised by the colonic mucosa in health and disease. 
